Featured Video Play Icon

TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!

We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three main locations in Hamburg (Germany), Hyderabad (India) and Lefkosia (Cyprus).

For information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a value-driven and patient-focused healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients ́ lives by creating pharmaceuticals more affordable, more available, and better than before.


Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities

Did you know that TIEFENBACHER GROUP heavily invests in its own manufacturing facilities to secure an efficient and reliable supply of our high-quality pharmaceuticals for patients around the world?

As fully integrated pharmaceutical company, we offer a competitive supply chain management through our two own manufacturing plants in India and Cyprus. Our facilities are equipped with sophisticated technology from the first manufacturing step throughout to the last packaging step and warehousing. We are flexible to manage small batch as well as high volume productions. While our SPC waiver site in Cyprus is your perfect plant for high volume production made in Europe, our FDA approved site in India is your ideal fit for special technologies and small batch production. Both sites are currently further enlarging their production capacities, equipment, and warehouse storage – to drive efficiency and meet the growing demand of our customers.

Our two own manufacturing sites as well as our global network of contract manufacturers allow us to manufacture nearly any kind of formulation and dosage form. No matter if a controlled drug or a special dosage form – our about 60 years experience and our excellent know how in terms of regulatory and quality requirements guarantee the best possible supply chain for you.

All our plants are equipped with highly qualified professionals and highest safety standards. This ensures full compliance with Good Manufacturing Practice (GMP). Apart from the most important governmental approvals, our sites are periodically inspected by leading pharmaceutical companies.

For further information about our manufacturing facilities and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


Featured Video Play Icon

Three successful days for TIEFENBACHER GROUP at CPhI 2021 – thanks for visiting us in Milano!

With over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma event CPhI has just come to an end. It was three very successful days for TIEFENBACHER GROUP presenting our latest product portfolio and innovations at Fiera Milano. After two years of mainly digital work it was a great experience to finally meet our valued customers and partners in person again. Our experts have come home with lots of new inspirations and business ideas and are already looking forward to reconnecting soon. Check out our short video to get an impression of our brand-new booth representing TIEFENBACHER GROUP as a global health pioneer.

For further information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a value-driven and patient-focused healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available and better than before.


Featured Video Play Icon

At TIEFENBACHER GROUP giving back to society is important to us: New school building in India

As a value-driven healthcare company, dedicated to improve the life of patients worldwide, we believe that it´s our responsibility to care about the environment and society – especially in the countries in which we operate.

That’s why we are happy to share that we have build up a new school next to our own R&D and manufacturing facilities in Hyderabad, India, to improve the education and health of the children in our neighborhood. The “Anganwadi school” follows international standards of Kindergarten and has already started to educate 25 children from Alinagar village in the age of 3-8. With this initiative we give underprivileged children from poor families the chance to have a better future through better education and nutrition.

Anganwadi is a type of rural child care center in India. They were started by the Indian government in 1975 as part of the Integrated Child Development Services program to improve the nutrition and health status of children and to reduce morbidity, mortality and school dropout – laying the foundation for holistic development of children.

For TIEFENBACHER GROUP it is a rewarding experience to give back to the community. Our caring culture is fundamental to achieve our purpose to make everyday life significantly better for people around the world. We will continue promoting education and health in various community engagement projects that are in line with our values and beliefs.

For further information about our corporate responsibility or our worldwide health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a value-driven and patient-focused healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available and better than before.


Reach out to TIEFENBACHER GROUP at CPhI in Milan from 9-11th Nov and discover our latest ideas to make pharmaceuticals more affordable, more available and better than before!

“Nothing can replace meeting each other in person!” says Oliver Schrader, Managing Director of Tiefenbacher Group. After nearly two years of mainly digital work, we are very excited to be back on the world´s leading pharma industry event CPhI in Milan to meet our valued customers and partners finally in person again.

Explore our brand-new booth representing Tiefenbacher Group as a global health pioneer and discover our latest product portfolio and innovations! Connect with our experts to discuss new business opportunities and ideas for improving the life of millions of patients worldwide!

CPhI 2021 will take place on November 9-11th at Fiera Milano, Italy. We’ll be happy to meet you at our stand 3H11. The arrangement of prescheduled meetings is highly appreciated due to Covid-19 and limited booth time and space. Please contact our team to request a meeting or send a meeting request to cphi@aet.eu.

TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on www.tiefenbachergroup.com


New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the antihistamine Bilastine

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why we are excited to share that we have successfully launched the first generic version of Bilastine (20 mg tablets) in Spain.

Bilastine is an innovative anti-allergy medicine improving the life of patients suffering from allergic symptoms, such as hay fever and urticaria. The second-generation antihistamine product helps to relieve nasal and non-nasal symptoms of seasonal rhinitis (like sneezing and red, streaming eyes) as well as urticaria caused symptoms (like itchy skin).

With this early market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment. Following our global market entry approach, a launch in several further international countries is already in preparation.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is as a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com


New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP

Swedish Life science company OnDosis and German B2B pharmaceutical company TIEFENBACHER GROUP initiate four new innovative development projects targeting ADHD, rare diseases, and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.

TIEFENBACHER GROUP is a pioneering healthcare company with innovative and best-in-class solutions along the entire pharmaceutical development value chain. The company’s vision is to improve patients’ lives by making a difference in tomorrow’s health. An idea that corresponds well with how OnDosis wants to revolutionize how patients take their medicines. “It feels fantastic to expand our existing collaboration with several new projects,” says Dr. Kristian Ruepp, Joint Managing Director, TIEFENBACHER GROUP.

Last year, the two companies began cooperating on an ADHD treatment that has already received attention in the USA. As an example, the OnDosis drug/device for ADHD was highlighted during APSARD, the annual general meeting of The American Professional Society of ADHD and Related Disorders.

“Whilst our first ADHD project fast approaches final stages of development, we are thrilled to partner up with TIEFENBACHER for no less than four more projects that will greatly expand our portfolio,” says Martin Olovsson, CEO OnDosis. “Some of the critical and heart-warming targets include helping those with serious rare diseases, and patients that have undergone an organ transplant. Two patient groups where finely tuned and individualized doses of the prescribed medications are critical to outcomes and necessary to for patients to live a better everyday life.”

The partnership aims to develop and commercialize products in the intersection between traditional drug-based medicine and digital therapeutics. The five products developed are planned for launch 2023 and onwards. The team at OnDosis consists of experts in developing and designing proprietary solutions, including intuitive, user-friendly, and connected devices that deliver medicine and enables digital solutions to be integrated. As a result, each patient’s specific needs can be met with individualized doses that the patient or the doctor can adjust should the need arise. The collection of data on dosing linked to outcomes open up a new field of a closed loop disease management. Ultimately, the goal is to achieve algorithm-based
dosing through predictive modeling leading to personalized treatments.

Another novelty is to dispense the drugs as pellets instead of pills or capsules, making them easier to consume.

TIEFENBACHER GROUP has significant expertise and experience in developing pharmaceuticals across all stages of development. Their expertise guarantees efficient development of medicines in a form that allows individual dosing whilst meeting the most rigorous quality and safety standards. Also, TIEFENBACHER’s leading competence within supply chain and B2B commercialization will be instrumental when the first products developed by Tiefenbacher and OnDosis reach the market in 2023-2024.

“One of our key focus areas is what we call ‘Beyond Imagination’, and OnDosis is the right partner when going there. Together, we will make a real difference when it comes to optimizing the effects of the medicine people take,” says Kristian Ruepp. “We want to give people a chance to live the life they deserve. For many, this is only possible with the right dose of their prescribed medication. In collaboration with Tiefenbacher, we have every chance to fulfill this vision,” Martin Olovsson concludes.

For further information around pharmaceuticals or other worldwide health solutions please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER GROUP plays an active role in the fast changing and innovative ecosystem of the pharmaceutical industry and healthcare. Please visit us on: www.tiefenbachergroup.com


Spreading of Post COVID-19 Disease „Black Fungus“ in India – TIEFENBACHER GROUP supports with Posaconazole Tablets

Black Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised patients. However, many patients who have survived their COVID-19 infection with the help of external oxygen support are now affected by black fungus. Physicians in India believe that an inadequate oxygen supply of COVID-19 patients may be the reason for this dangerous development.

With Posaconazole tablets Tiefenbacher produces one of the most effective treatments against Black Fungus and is now supporting India to push back this disease fast. “When we heard about the problems with Black Fungus in India we directly decided to change our production plans and produce as fast as possible Posaconazole tablets for India. We hope to be able to help as many Black Fungus patients as fast as possible.” says Oliver Schrader, Joint Managing Director of Tiefenbacher Group.


TIEFENBACHER GROUP announces global launch of TIEFENBACHER MEDICAL DEVICES

After more than five years in operation, TIEFENBACHER GROUP will transfer its medical device business into a new stand-alone company: TIEFENBACHER MEDICAL DEVICES.

The launch follows TIEFENBACHER GROUP´s strategy to offer better patient therapies by combining established drug-based medicines with medical devices & digital health. TIEFENBACHER MEDICAL DEVICES is focused on medical devices for respiratory treatments and multiple other innovative drug-device combination products for individualized treatments in globally relevant disease areas.

Please have a look at our Website: www.tiefenbachergroup.com/medical-device/

About TIEFENBACHER MEDICAL DEVICES
TIEFENBACHER MEDICAL DEVICES is developing medical devices as part of combination products and offering eHealth solutions where relevant. We leverage the full potential during drug-device combination product developments and keep people safe and healthy by maximizing treatment outcomes while minimizing healthcare spends. Driven by patient demands, we are managing the entire innovative process from concept to market entry and create healthcare opportunities across the globe as well as accelerating routes to market.

For further information around medical devices or other worldwide eHealth solutions please contact TIEFENBACHER MEDICAL DEVICES: info@aet.eu

TIEFENBACHER GROUP plays an active role in the fast changing and innovative ecosystem of the pharmaceutical industry and healthcare. Please visit us on: www.tiefenbachergroup.com


TIEFENBACHER PHARMACEUTICALS announces global launch of Teriflunomide making multiple sclerosis therapy more affordable and better available worldwide

TIEFENBACHER PHARMACEUTICALS, part of TIEFENBACHER GROUP, has successfully developed a global dossier for a generic version of Teriflunomide 7 mg and 14 mg film-coated tablets.  

Teriflunomide is an important part of the therapy of multiple sclerosis and the global roll-out of the product in more than 40 countries will make this therapy more affordable and better available for the over 2,8 million patients worldwide.  

The product was developed and is commercially produced at our Indian manufacturing site TIEFENBACHER LABORATORIES in Hyderabad and at Combino Pharm Ltd.   

The formulation has successfully passed four bioequivalence studies against reference products from three different markets. The product is already approved in Australia, Canada, New Zealand, and the US. Additional filings in Europe, South America and South Africa are under preparation and will take place this year in line with data exclusivity expiry.  

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALSinfo@aet.eu 

TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com

Disclaimer: Teriflunomide, which is subject to patent prosecution, is currently not offered or made available in countries where patents are in force.